Ultime notizie per XBiotech (NASDAQ:XBIT) Azioni

XBiotech

XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.

XBiotech Inc

Trading Ideas

XBIT

XBiotech Shares Resume Trade

Trading Halt: Halt status updated at 9:45:00 AM ET: Quotation Resumption: News and Resumption Times

Biotech

News

General

XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

Trading Halt: Halted at 8:55:10 a.m. ET - Trading Halt: Halt News Pending

Tuesday, XBiotech&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>)&nbsp;announced data from its Phase 1/Phase 2, 1-BETTER Study for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39383607/xbiotech-results-from-randomized-double-blinded-phase-12-study-suggest-potential-breakthrough-trea" rel="noreferrer noopener">advanced pancreatic cancer</a>.
The study examined the Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV)), which is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less-than-ideal survival outcomes.
Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the company believes it might potentially also improve tolerability of the chemotherapy.
The Phase 1 portion was a dose escalation study in metastatic pancreatic cancer patients to determine if dose-limiting toxicities occurred in combination with the ON+5FU+LV regimen in a second- or third-line setting.
DLTs were not expected with Natrunix and none were seen. The Natrunix dose in the Phase 2 portion was thus the highest dose used in the Phase 1 portion.
The primary endpoint for the Phase 2 study was to assess the safety and tolerability of Natrunix when used with the ON+5FU+LV combination.
Overall, there were fewer adverse events (AEs) during the 24-week treatment period for the Natrunix arm compared to placebo (297 vs 336), with markedly fewer events in specific categories of adverse events during that time.
Subjects receiving the Natrunix ON+5FU+LV regimen also had about a 33% reduction in hospitalization (80 days versus 120 days).
Subjects receiving the Natrunix combination also reported a 22% reduction in fatigue, 32% improved appetite, and 41% reduction in pain.
The incidence of severe diarrhea was twofold (9% versus 19%) lower during the 24-week treatment regimen for patients receiving the Natrunix + ON+5FU+LV combination compared to placebo + ON+5FU+LV.
Overall Survival (OS) is one of the secondary endpoints for the Phase 2 study. The data highlights the observation that no subjects in the placebo ON+5FU+LV group (n=32) survived for longer than 330 days, whereas eight subjects in the Natrunix ON+5FU+LV arm (n=33) were still alive as of day 330.
Considering the small sample size, the borderline statistically significant p-value of p = 0.096 suggests prolonged survival for subjects receiving the Natrunix regimen.
Price Action: XBIT shares are down 9.54% at $5.50 at last check Tuesday.
Image by PDPics from Pixabay

Equities

Health Care

Movers

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

XBiotech shares are trading higher after the company shared results from the 1-BETTER study for advanced pancreatic cancer.

XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix Arm Compared To Placebo, With Markedly Fewer Events In Specific Categories Of Adverse Events During That Time

XBiotech&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV), a regimen that is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less then ideal survival outcomes. Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the Company believes it might potentially also improve tolerability of the chemotherapy. &nbsp;
The Phase 1 portion was a dose escalation study in metastatic pancreatic cancer patients to determine if dose limiting toxicities (DLTs) occurred in combination with the ON+5FU+LV regimen in second- or third-line setting. DLTs were not expected with Natrunix and none were seen. The Natrunix dose in the Phase 2 portion was thus the highest dose used in the Phase 1 portion.

XBiotech Shares Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment For Advanced Pancreatic Cancer

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares rose 23.1% to $1.49 during Monday's pre-market session. The market value of their outstanding shares is at $21.4 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 19.8% to $0.75. The market value of their outstanding shares is at $4.3 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 17.61% to $0.37. The company's market cap stands at $11.1 million. </li>
<li>scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) stock increased by 16.47% to $6.22. The company's market cap stands at $223.0 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares increased by 16.32% to $0.29. The company's market cap stands at $2.9 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares rose 15.95% to $5.67. The company's market cap stands at $34.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock declined by 20.9% to $1.5 during Monday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>XBiotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) shares fell 20.44% to $3.7. The company's market cap stands at $112.6 million. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) shares declined by 17.86% to $5.75. The market value of their outstanding shares is at $6.0 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 13.3% to $0.91. The company's market cap stands at $7.4 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 11.17% to $0.37. The market value of their outstanding shares is at $16.5 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares decreased by 9.7% to $0.27. The company's market cap stands at $57.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BFRG

BNOX

CELU

LIFW

NEXI

OPGN

SCPH

SNTI

SXTP

TBIO

12 Health Care Stocks Moving In Monday's Pre-Market Session

XBiotech Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin. &nbsp;
The primary objective of the Phase I study is to evaluate safety and pharmacokinetics of Hutrukin in healthy volunteers. Sequential dose escalation was conducted using three cohorts of subjects, each receiving a single intravenous infusion of either placebo or Hutrukin, with eight subjects in each cohort.
Hutrukin is a candidate drug being developed to reduce brain injury following ischemic stroke. Globally, one in four people over age 25 will experience a stroke—the leading cause of disability and second leading cause of death in the world. An ischemic stroke occurs when a blood clot obstructs a blood vessel that supplies the blood to the brain. Blockage of blood flow to the brain results in brain injury, loss of brain function, or death.
Emergency treatment for stroke includes "clot-busting" drugs or mechanical catheters to re-open arteries, both of which are associated with a phenomenon known as&nbsp;reperfusion injury. Reperfusion injury is the damage that occurs to previously healthy brain tissue after a clot is removed from the artery and blood supply is returned to the healthy but hypoxic brain tissue. This secondary damage is believed to be the result of an inflammatory response resulting from the return of blood cells to the region of the brain that had been previously deprived of blood and oxygen (which is the hypoxic brain tissue).
When administered immediately prior to artery-opening procedures, Hutrukin may reduce the inflammatory injuries associated with reperfusion. No drug or treatment is currently available to reduce or prevent reperfusion injury. Hutrukin potentially represents a unique and major advance for stroke victims.

XBiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke

<h3>Gainers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 13.5% to $0.63 during Tuesday's after-market session. Trading volume for this security closed at 668.1K, accounting for 276.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.4 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) shares moved upwards by 11.99% to $1.4. The company's market cap stands at $109.3 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares moved upwards by 10.46% to $0.95. The market value of their outstanding shares is at $11.1 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) stock moved upwards by 8.19% to $0.55. The market value of their outstanding shares is at $83.7 million. </li>
<li>Longeveron Inc. - Subscription Right (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVNR#NASDAQ">LGVNR</a>) shares increased by 7.49% to $0.04. </li>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) stock increased by 6.23% to $0.64. The company's market cap stands at $31.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XBiotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) stock fell 6.7% to $4.49 during Tuesday's after-market session. The market value of their outstanding shares is at $136.6 million. </li>
<li>Carmell Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock declined by 5.61% to $4.04. The company's market cap stands at $93.2 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) stock fell 5.38% to $0.27. At the close, Novo Integrated Sciences's trading volume reached 20.9 million shares. This is 74.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $43.2 million. </li>
<li>EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) stock declined by 5.09% to $8.96. The market value of their outstanding shares is at $313.4 million. </li>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) stock fell 5.08% to $0.71. The company's market cap stands at $21.6 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) shares decreased by 4.96% to $0.38. Today's trading volume for this security ended up closing at 243.6K shares, which is 86.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

CTCX

EYPT

HLTH

LGVNR

NVOS

ORGS

VNRX

VRPX

YTEN

12 Health Care Stocks Moving In Tuesday's After-Market Session

XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study&mdash;a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer. 
&nbsp;
Natrunix is indistinguishable from a naturally occurring antibody present in a healthy human. Natrunix binds and neutralizes a potent substance, a so called cytokine known as interleukin-1a (IL-1a), that causes connective tissue breakdown, growth of new blood vessels, and recruitment of white blood cells. Malignant tumors, like pancreatic cancer, stimulate the body&#39;s production of IL-1a that induce tumor neovascularization, growth and spread. Additionally, IL-1a acts as an alarm signal when there is body injury (such as when tumors grow), enhancing pain perception, metabolism, appetite, fatigue, and anxiety. The insult from chemotherapy also induces IL-1a production. Adding Natrunix to your chemotherapy regimen may therefore provide numerous benefits, including anti-tumor activity, reduction in chemotherapy side effects, improvement in chemotherapy activity&mdash;including increasing the number of cycles of therapy that can be tolerated while improving quality of life.
Twenty-two leading cancer centers across the United States have been involved in the Phase I/II study. Pancreatic cancer is the 4th&nbsp;leading cause of cancer death in the United States and the incidence has been increasing steadily since 2000. In 2022, an estimated 50,000 people died from pancreatic cancer in the United States. The Natrunix antibody therapy represents a groundbreaking approach to therapy.
The Phase II portion enrolled 65 subjects using the maximum dose studied from the Phase I study that were randomized on a 1:1 basis to receive either Natrunix in combination with ONIVYDE+LV+5-FU (Arm 1), or placebo plus the chemotherapy combination. Key endpoints in the Phase II portion are safety and tolerability, progression-free survival, overall survival and time-to-treatment-failure.

XBiotech Announces Enrollment Completion Of Phase II, Placebo Controlled, Multicenter Study For Natrunix In Pancreatic Cancer

&nbsp;XBiotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA). 
&nbsp;
The primary endpoint of the Phase II is the American College of Rheumatology (ACR)&nbsp;20%&nbsp;Response (ACR 20) rate at 12 weeks. Secondary and exploratory endpoints include ACR 50, ACR 70, numerical rating scale (NRS) for pain score, inflamed and painful joint counts, Health Assessment Questionnaire Disability Index (HAQ-DI), Routine Assessment of Patient Index Data 3 (RAPID-3), Clinical Disease Activity Index (CDAI) and safety. These endpoints reflect the expectation that Natrunix may provide needed improvement with respect to pain, tenderness, mobility of joints and quality of life. Approximately 210 subjects will be enrolled into three different arms in the study. All subjects will receive methotrexate (MTX) and be randomized to receive either one of two doses of Natrunix or placebo.
Natrunix is a monoclonal antibody indistinguishable from a naturally occurring antibody from a human donor. Natrunix binds and neutralizes the action of one of the most potent inflammation-causing substances known&mdash;interleukin-1. For decades, interleukin-1 was seen as the key target for drugs to treat RA. However, to date, drugs that block interleukin-1 have not lived up to expectations as therapies for RA. XBiotech believes it has solved this puzzle.
Interleukin-1 actually describes two separate and distinct molecules&mdash;IL-1a and IL-1b&mdash;that are produced at different times and places in the body. XBiotech is the first to develop candidate therapies&mdash;like Natrunix&mdash;that directly and specifically neutralize IL-1a. In recent years, world-class research has shown that in many cases IL-1a may be the crucial target for blocking disease-causing activities of the interleukin-1 inflammatory pathway. Natrunix thus holds promise as a new generation anti-inflammatory therapy for arthritis. As a naturally derived human antibody, it is also by design expected to be among the safest and best tolerated medicines ever developed.
One in four adults, or over 50 million people in the United States are currently affected by Rheumatoid Arthritis, including&nbsp;33%&nbsp;of those between the ages of 45-64 and&nbsp;50%&nbsp;of person over 65 years of age. The number of persons affected by RA is expected to increase, with the CDC predicting that by the year 2040, 78.4 million adults, will suffer from RA in the United States. In addition, it is expected that 300,000 children will suffer from juvenile arthritis (Arthritis Foundation, 2023).
About True Human&trade; Therapeutic Antibodies
Natrunix was discovered by XBiotech researchers at the Company&#39;s headquarters in Austin, Texas. XBiotech&#39;s True Human&trade; antibodies are derived without modification from individuals who possess natural immunity to certain diseases. By harnessing the body&#39;s natural immunity to cure disease, True Human&trade; antibodies have the potential to revolutionize medicine.

XBiotech Announces First Patient Begins Novel Natrunix Therapy In Phase II Rheumatoid Arthritis Clinical Trial

Xbiotech Announces FDA Authorizes Phase II Study For Natrunix In Rheumatoid Arthritis Patients

<h3>Gainers</h3>
<ul>
<li>Smart for Life, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smfl#NASDAQ">SMFL</a>) shares climbed 86.2% to $4.32. Smart for Life announced Wednesday that it had executed a strategic agreement with CloudKitchens for rapid local delivery of its new line of innovative, proprietary, and healthy high-protein ice cream bars.</li>
<li>Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) gained 63.6% to $1.1781 after the company announced it completed the first clinical evaluation of the new Pure-Vu Gastro in upper gastrointestinal procedures to support FDA submission.</li>
<li>WeTrade Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wetg#NASDAQ">WETG</a>) shares surged 52.7% to $0.0581 after dropping around 15% on Tuesday. WeTrade Group recently received a notice of noncompliance from Nasdaq because it failed to timely file its 2022 annual report on form 10-K with the SEC.</li>
<li>National Western Life Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwli#NASDAQ">NWLI</a>) jumped 35% to $360.76. National Western Life Group reported exploration of strategic alternatives.</li>
<li>Sunrise New Energy Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/epow#NASDAQ">EPOW</a>) shares gained 30.1% to $2.5113 after the company reported a sharp rise in sales for the fiscal year ended Dec. 31, 2022.</li>
<li>Impel Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impl#NASDAQ">IMPL</a>) jumped 28.4% to $1.40.</li>
<li>XBiotech Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xbit#NASDAQ">XBIT</a>) shares gained 27.9% to $4.45. XBiotech commenced tender offer to purchase up to $80 million worth of its shares at price not greater than $4.00 nor less than $3.80 per share.</li>
<li>Trinity Place Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tphs#NYSE">TPHS</a>) jumped 27.2% to $0.6362.</li>
<li>Netcapital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncpl#NASDAQ">NCPL</a>) gained 22.9% to $1.8550 after dropping over 9% on Tuesday.</li>
<li>JE Cleantech Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jcse#NASDAQ">JCSE</a>) shares gained 22.7% to $0.64 after dropping 13% on Tuesday.</li>
<li>Anghami Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angh#NASDAQ">ANGH</a>) jumped 20% to $1.4050. Anghami filed 2022 annual report with 37% revenue growth.</li>
<li>Tingo Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tio#NASDAQ">TIO</a>) jumped 17.7% to $4.51.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crvs#NASDAQ">CRVS</a>) rose 17.7% to $2.79. Corvus Pharmaceuticals will present new CPI-818 data at International Conference on Malignant Lymphoma on June 13-17.</li>
<li>SaverOne 2014 Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/svre#NASDAQ">SVRE</a>) gained 16.2% to $1.58.</li>
<li>MedAvail Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdvl#NASDAQ">MDVL</a>) surged 15.5% to $0.26.</li>
<li>ProPetro Holding Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pump#NYSE">PUMP</a>) gained 15.5% to $7.49. ProPetro plans $100 million share repurchase program.</li>
<li>Triumph Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgi#NYSE">TGI</a>) climbed 14.7% to $12.06 after the company reported better-than-expected Q4 financial results and issued guidance.</li>
<li>GD Culture Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdc#NASDAQ">GDC</a>) gained 13.7% to $7.20. The company released its quarterly report in a Form10 filing.</li>
<li>FLJ Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flj#NASDAQ">FLJ</a>) climbed 13.6% to $0.5348.</li>
<li>Western Alliance Bancorporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wal#NYSE">WAL</a>) gained 9.9% to $34.71 after the company released an investor update. The company said QTD deposit growth exceeded $2 billion as of May 12th.</li>
<li>P3 Health Partners Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/piii#NASDAQ">PIII</a>) gained 9% to $3.50.</li>
<li>Top KingWin Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcjh#NASDAQ">TCJH</a>) shares climbed 7.8% to $7.50 after gaining 9% on Tuesday.</li>
<li>Comerica Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cma#NYSE">CMA</a>) jumped 7.7% to $36.52. Shares of bank stocks traded higher after Western Alliance released an investor update showing QTD deposit growth exceeded $2 billion as of May 12th. This has helped ease some ongoing concerns over the financial sector.</li>
<li>Keysight Technologies Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/keys#NYSE">KEYS</a>) gained 7.7% to $157.80 after the company reported better-than-expected earnings results for its second quarter on Tuesday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cerberus Cyber Sentinel Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciso#NASDAQ">CISO</a>) fell 33.3% to $ 0.1999 after the company reported pricing of $4.0 million registered direct offering.</li>
<li>Intercept Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icpt#NASDAQ">ICPT</a>) shares fell 21.3% to $12.76 following a report suggesting FDA staff concluded Intercept Pharmaceuticals&#39; OCA can cause significant drug-induced liver injury.</li>
<li>ASP Isotopes Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aspi#NASDAQ">ASPI</a>) dropped 18.4% to $0.3670.</li>
<li>Powerbridge Technologies Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbts#NASDAQ">PBTS</a>) shares fell 16.4% to $0.0735 after climbing over 33% on Tuesday.</li>
<li>Airspan Networks Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mimo#NYSE">MIMO</a>) dropped 16% to $0.2865.</li>
<li>EVgo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evgo#NASDAQ">EVGO</a>) fell 14.8% to $4.8850 after the company announced an offering of Class A common stock.</li>
<li>Agilysys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agys#NASDAQ">AGYS</a>) declined 14.6% to $66.11 after the company reported Q4 financial results.</li>
<li>1847 Holdings LLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/efsh#NYSE">EFSH</a>) dropped 12.1% to $0.58. 1847 recently reported a year-over-year increase in Q1 sales results.</li>
<li>Kyndryl Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kd#NYSE">KD</a>) fell 11.5% to $12.72 after the company reported mixed Q1 financial results and issued FY24 revenue guidance below estimates.</li>
<li>The Container Store Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tcs#NYSE">TCS</a>) shares dropped 11.5% to $2.3950. The Container Store Group reported upbeat earnings for its fourth quarter, while sales missed estimates.</li>
<li>MGO Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgol#NASDAQ">MGOL</a>) fell 11.4% to $1.13. MGO Global shares dropped 18% on Tuesday after posting a first-quarter loss.</li>
<li>Kubient, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kbnt#NASDAQ">KBNT</a>) dropped 11% to $0.4539.</li>
<li>Shengfeng Development Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfwl#NASDAQ">SFWL</a>) dipped 10.6% to $6.52.</li>
<li>Ardelyx, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ardx#NASDAQ">ARDX</a>) declined 10.3% to $3.9999. Ardelyx announced FDA acceptance and six-month review for resubmission of new drug application of XPHOZAH.</li>
<li>Intapp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inta#NASDAQ">INTA</a>) dropped 10.1% to $39.63 after the company announced a proposed public offering of 2 million shares of common stock. Also, some stockholders intend to offer 4.25 million shares of the company&#39;s stock in the offering.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/maxn#NASDAQ">MAXN</a>) dipped 10% to $28.05 after the company announced the pricing and upsize of a public offering of ordinary shares.</li>
<li>Stronghold Digital Mining, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdig#NASDAQ">SDIG</a>) declined 8.3% to $5.44. Stronghold Digital Mining recently announced a 1-for-10 reverse stock split.</li>
<li>Doximity, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docs#NYSE">DOCS</a>) fell 8% to $31.18 after the company issued weak sales guidance.</li>
<li>GSI Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gsit#NASDAQ">GSIT</a>) shares dropped 6.3% to $4.06 after reporting a wider fourth-quarter loss.</li>
<li>Hess Midstream LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hesm#NYSE">HESM</a>) shares dropped 5.4% to $27.45 after the company reported pricing of secondary public offering of Class A shares.</li>
<li>OneSpaWorld Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/osw#NASDAQ">OSW</a>) shares declined 4.4% to $10.52 as the company reported pricing of secondary offering of common shares by selling shareholders.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/05/32445263/ethereum-dips-below-1-800-pepe-becomes-top-loser"> Ethereum Dips Below $1,800; Pepe Becomes Top Loser</a>

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

AGYS

ANGH

ARDX

ASPI

CISO

CRVS

DOCS

EFSH

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

EVGO

GSIT

HESM

ICPT

IMPL

INTA

JCSE

KBNT

KEYS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MDVL

MGOL

Airspan Networks Holdings Inc. Common Stock

MIMO

MOTS

NCPL

NWLI

PBTS

PIII

PUMP

SDIG

SFWL

SMFL

SVRE

TCJH

TPHS

WETG

Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

WIIM

XBiotech shares are trading higher after the company commenced a tender offer to purchase up to $80 million worth of its shares.

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.37% to 33,135.37 while the NASDAQ rose 0.39% to 12,391.68. The S&amp;P 500, also rose, gaining, 0.45% to 4,128.33.
Check This Out: <a href="https://www.benzinga.com/news/23/05/32444049/top-5-consumer-stocks-that-may-plunge-this-quarter"> Top 5 Consumer Stocks That May Plunge This Quarter</a>
&nbsp; 
<h3>Leading and Lagging Sectors</h3>
<ul>
<li>Consumer discretionary shares rose by 1.2% on Wednesday. Meanwhile, top gainers in the <a href='https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/'>sector</a> included United Homes Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uhg#NASDAQ">UHG</a>), up 21%, and i Purple Innovation, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prpl#NASDAQ">PRPL</a>), up 9%.</li>
<li>In trading on Wednesday, health care shares fell 0.4%.</li>
</ul>

&nbsp; 
<h3>Top Headline</h3>

U.S. housing starts rose 2.2% month-over-month to an annualized rate of 1.401 million in April, versus market expectations of 1.4 million.
Building permits in the U.S. dropped 1.5% to an annual rate of 1.416 million in April.
&nbsp; 
<h3>Equities Trading UP</h3>
<ul>
<li>Smart for Life, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smfl#NASDAQ">SMFL</a>) shares shot up 46% to $3.38. Smart for Life announced Wednesday that it had executed a strategic agreement with CloudKitchens for rapid local delivery of its new line of innovative, proprietary, and healthy high-protein ice cream bars.</li>
<li>Shares of GD Culture Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdc#NASDAQ">GDC</a>) got a boost, shooting 20% to $7.61. The company released its quarterly report in a Form10 filing.</li>
<li>XBiotech Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xbit#NASDAQ">XBIT</a>) shares were also up, gaining 19% to $4.1350. XBiotech commenced tender offer to purchase up to $80 million worth of its shares at price not greater than $4.00 nor less than $3.80 per share.</li>
</ul>

&nbsp; 
<h3>Equities Trading DOWN</h3>
<ul>
<li>Intercept Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icpt#NASDAQ">ICPT</a>) shares dropped 26% to $11.95 following a report suggesting FDA staff concluded Intercept Pharmaceuticals&#39; OCA can cause significant drug-induced liver injury.</li>
<li>Shares of Kyndryl Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kd#NYSE">KD</a>) were down 16% to $12.12 after the company reported mixed Q1 financial results and issued FY24 revenue guidance below estimates.</li>
<li>EVgo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evgo#NASDAQ">EVGO</a>) was down, falling 13% to $5.01 after the company announced an offering of Class A common stock.</li>
</ul>

Also Check This Out: <a href="https://www.benzinga.com/news/23/05/32444287/wall-streets-most-accurate-analysts-say-hold-these-3-tech-and-telecom-stocks-delivering-high-dividen"> Wall Street&#39;s Most Accurate Analysts Say Hold These 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a>
&nbsp; 
<h3>Commodities</h3>

In commodity news, oil traded down 0.1% to $70.85 while gold traded down 0.3% at $ 1,987.80.
Silver traded down 0.1% to $23.86 on Wednesday while copper rose 1.5% to $3.7230.
Stocks of crude oil in the US rose by 3.69 million barrels in the latest week, following a 3.618 million barrel growth a week ago, the API said Tuesday.
&nbsp; 
<h3>Euro zone</h3>

European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.1%, London&rsquo;s FTSE 100 fell 0.1% while Spain&rsquo;s IBEX 35 Index rose 0.1% The German DAX rose 0.4%, French CAC 40 slipped 0.1% and Italy&rsquo;s FTSE MIB Index declined 0.1%.
The Eurozone&rsquo;s consumer price inflation increased to 7.0% in April versus the prior month&#39;s 13-month low level of 6.9%. Passenger car registrations in the European Union surged 17.2% year-over-year to 803,188 units in April.
Italy recorded a trade surplus of EUR 7.5 billion in March, versus a year-ago gap of EUR 0.8 billion. The unemployment rate in France came in steady at 7.1% for the first quarter.
&nbsp; 
<h3>Asia Pacific Markets</h3>

Asian markets closed mostly lower on Wednesday, with Japan&rsquo;s Nikkei 225 gaining 0.84%, Hong Kong&rsquo;s Hang Seng Index dropping 2.09% and China&rsquo;s Shanghai Composite Index dropping 0.21%. India&rsquo;s S&amp;P BSE Sensex fell 0.6%.
The Japanese economy grew by 1.6% on an annualized basis in the first quarter, while industrial production in Japan increased by 1.1 % month-over-month in March. Average new home prices in China&#39;s major cities declined by 0.2% year-over-year during April. Australia&#39;s wage price index rose by 3.7% year-over-year in the first quarter.
&nbsp; 
<h3>Economics</h3>
<ul>
<li>U.S. housing starts rose 2.2% month-over-month to an annualized rate of 1.401 million in April, versus market expectations of 1.4 million.</li>
<li>Building permits in the U.S. dropped 1.5% to an annual rate of 1.416 million in April.</li>
</ul>

Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/05/32444261/12-5m-bet-on-this-technology-stock-check-out-these-4-stocks-insiders-are-buying"> $12.5M Bet On This Technology Stock? Check Out These 4 Stocks Insiders Are Buying</a>
&nbsp; 
<h3>COVID-19 Update</h3>

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 106,831,280 cases with around 1,163,290 deaths. India confirmed a total of at least 44,983,150 cases and 531,790 deaths, while France reported over 40,050,710 COVID-19 cases with 167,050 deaths. In total, there were at least 688,507,400 cases of COVID-19 worldwide with more than 6,875,780 deaths.
&nbsp;

Earnings

Eurozone

Commodities

Global

Intraday Update

PRPL

Dow Jumps Over 100 Points; US Housing Starts Rise In April

Buybacks

XBiotech Commences Tender Offer To Purchase Up To $80M Worth Of Its Shares At Price Not Greater Than $4.00 Nor Less Than $3.80 Per Share

&nbsp;XBiotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. 
&nbsp;
Hutrukin is being developed as a novel treatment to reduce brain injury following ischemic stroke. There are more than 10 million ischemic strokes each year&mdash;the leading cause of death and morbidity in the world today. An ischemic stroke occurs when a blood clot forms in a blood vessel that supplies blood flow to brain. Blockage of blood flow to the brain results in brain injury, loss of brain function or death.
Emergency use of &quot;clot-busting&quot; drugs or mechanical catheters to re-open arteries after a stroke is associated with a phenomenon known as&nbsp;reperfusion injury. Reperfusion injury is where the return of blood supply after removing the clot from the artery results in increased brain injury or death. Reperfusion injury is believed to be the result of a massive inflammatory response caused by blood cells as they flow back into the region of the brain that was deprived of blood supply (and oxygen).
Hutrukin therapy is intended to be provided immediately prior to the clot-busting procedure, where the drug may reduce inflammatory injury associated with reperfusion. There is currently no drug known to be effective to reduce reperfusion injury. Hutrukin could, therefore, potentially represent a significant advance in the management of stroke patients.
The current Phase I study will evaluate three dose levels of Hutrukin for safety and will measure the corresponding blood levels of Hutrukin with increasing doses. Findings will guide dosing and safety expectations for the next phase of studies.
About True Human&trade; Therapeutic Antibodies
XBiotech&#39;s True Human&trade; antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech&#39;s True Human&trade; antibodies have the potential to harness the body&#39;s natural immunity to fight disease with increased safety, efficacy and tolerability.

XBiotech Announces First Subject Enrollment In Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke

<h1>&nbsp;</h1>
On Monday, 79 companies reached new 52-week lows.
<h2>Facts of Interest About Today&#39;s 52-Week Lows:</h2>
<ul>
<li>The company with the largest market cap to set a new 52-week low was Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).</li>
<li>Baudax Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BXRX#NASDAQ">BXRX</a>) was the smallest company when considering market cap to set a new 52-week low.</li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>)&#39;s stock moved significantly downwards, trading down 20.68% to reach a new 52-week low.</li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>)&#39;s stock showed potential to rebound, rebounding up 0.0% after reaching a new 52-week low.</li>
</ul>
Stocks dropping to new 52-week lows on Monday:
<ul>
<li>Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares set a new yearly low of $9.92 this morning. The stock was up 0.1% on the session.</li>
<li>Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares made a new 52-week low of $5.65 on Monday. The stock was down 2.77% for the day.</li>
<li>SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) stock set a new 52-week low of $4.49 on Monday, moving down 1.3%.</li>
<li>Ginkgo Bioworks Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) stock set a new 52-week low of $1.91 on Monday, moving down 1.76%.</li>
<li>QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares made a new 52-week low of $6.69 on Monday. The stock was down 4.05% for the day.</li>
<li>ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares reached a new 52-week low of $22.01 on Monday morning, moving down 13.46%.</li>
<li>Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) stock broke to a new 52-week low of $8.51 on Monday. Shares of the company traded down 7.33%.</li>
<li>Aurora Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) stock broke to a new 52-week low of $1.28 on Monday. Shares of the company traded down 3.7%.</li>
<li>Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) shares were down 1.7% for the day, having made a 52-week low of $17.60.</li>
<li>Olo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) stock achieved a new 52-week low on Monday morning, hitting $6.85 and moving down 1.97%.</li>
<li>OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares hit a yearly low of $1.42. The stock was down 2.04% on the session.</li>
<li>Ferroglobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSM#NASDAQ">GSM</a>) stock set a new 52-week low of $4.45 on Monday, moving down 3.03%.</li>
<li>Solid Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) shares fell to $4.45 on Monday, setting a new 52-week low with a shift of down 0.99%.</li>
<li>First Foundation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NASDAQ">FFWM</a>) stock broke to a new 52-week low of $13.51 on Monday. Shares of the company traded down 2.38%.</li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares reached a new 52-week low of $4.29 on Monday morning, moving down 2.91%.</li>
<li>Broadmark Realty Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRMK#NYSE">BRMK</a>) shares set a new 52-week low of $4.11. The stock traded down 0.6%.</li>
<li>Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) shares made a new 52-week low of $2.44 on Monday. The stock was down 3.49% for the day.</li>
<li>Vacasa (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) shares set a new 52-week low of $1.45. The stock traded down 0.99%.</li>
<li>Aeva Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) stock hit $1.51 on Monday morning, setting a new 52-week low for a change of down 1.91%.</li>
<li>Cyxtera Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYXT#NASDAQ">CYXT</a>) shares moved down 7.49% on Monday to hit a new 52-week low of $1.70, drifting down 7.49%.</li>
<li>Unisys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) shares fell to $4.17 on Monday, setting a new 52-week low with a shift of down 1.52%.</li>
<li>ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) stock hit a new 52-week low of $3.53. The stock was up 0.42% on the session.</li>
<li>Motorcar Parts of America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPAA#NASDAQ">MPAA</a>) shares hit a yearly low of $12.36. The stock was down 2.29% on the session.</li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) shares hit a yearly low of $1.25. The stock was up 1.56% on the session.</li>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) shares hit a yearly low of $4.00. The stock was down 0.25% on the session.</li>
<li>Tattooed Chef (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTCF#NASDAQ">TTCF</a>) shares reached a new 52-week low of $1.54 on Monday morning, moving down 2.5%.</li>
<li>USD Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USDP#NYSE">USDP</a>) stock hit $3.40 on Monday morning, setting a new 52-week low for a change of down 1.58%.</li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) stock hit a yearly low of $1.85. The stock was 0.0% (flat) for the day.</li>
<li>ATI Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#NYSE">ATIP</a>) shares moved down 7.12% on Monday to hit a new 52-week low of $0.46, drifting down 7.12%.</li>
<li>XBiotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) shares made a new 52-week low of $3.06 on Monday. The stock was 0.0% (flat) for the day.</li>
<li>Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) stock hit a new 52-week low of $12.84. The stock was up 3.38% on the session.</li>
<li>Pardes Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDS#NASDAQ">PRDS</a>) shares moved up 3.55% on Monday to hit a new 52-week low of $0.95, drifting up 3.55%.</li>
<li>IronNet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRNT#NYSE">IRNT</a>) shares made a new 52-week low of $0.45 on Monday. The stock was up 0.2% for the day.</li>
<li>GAN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAN#NASDAQ">GAN</a>) shares hit a yearly low of $1.20. The stock was down 3.89% on the session.</li>
<li>MedAvail Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDVL#NASDAQ">MDVL</a>) stock hit $0.48 on Monday morning, setting a new 52-week low for a change of down 1.91%.</li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) shares set a new 52-week low of $0.59. The stock traded down 3.86%.</li>
<li>LENSAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNSR#NASDAQ">LNSR</a>) stock hit a yearly low of $3.46. The stock was up 5.16% for the day.</li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) shares moved down 0.05% on Monday to hit a new 52-week low of $1.40, drifting down 0.05%.</li>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock broke to a new 52-week low of $0.76 on Monday. Shares of the company traded down 3.33%.</li>
<li>Golden Sun Education Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSUN#NASDAQ">GSUN</a>) stock drifted down 10.77% on Monday morning to hit a new 52-week low of $1.79.</li>
<li>Evolve Transition Infr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SNMP#AMEX">SNMP</a>) shares were down 9.61% for the day, having made a 52-week low of $0.15.</li>
<li>Comstock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) stock broke to a new 52-week low of $0.33 on Monday. Shares of the company traded down 3.54%.</li>
<li>Orbital Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OIG#NASDAQ">OIG</a>) shares reached a new 52-week low of $0.19 on Monday morning, moving down 4.55%.</li>
<li>Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) shares hit a yearly low of $1.12. The stock was down 16.54% on the session.</li>
<li>AlerisLife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALR#NASDAQ">ALR</a>) shares hit a yearly low of $0.75. The stock was down 1.94% on the session.</li>
<li>Shift Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFT#NASDAQ">SFT</a>) stock dropped to a yearly low on Monday of $0.28. Shares traded down 2.3%.</li>
<li>TuanChe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) shares made a new 52-week low of $1.09 on Monday. The stock was down 1.77% for the day.</li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) shares fell to $0.45 on Monday, setting a new 52-week low with a shift of up 0.49%.</li>
<li>Digital Ally (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares reached a new 52-week low of $0.30 on Monday morning, moving down 1.04%.</li>
<li>Astrotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTC#NASDAQ">ASTC</a>) shares were down 5.48% for the day, having made a 52-week low of $0.32.</li>
<li>China Natural Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHNR#NASDAQ">CHNR</a>) stock set a new 52-week low of $0.39 on Monday, moving down 5.98%.</li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares moved down 1.72% on Monday to hit a new 52-week low of $1.13, drifting down 1.72%.</li>
<li>Troika Media Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRKA#NASDAQ">TRKA</a>) stock hit $0.19 on Monday morning, setting a new 52-week low for a change of down 16.78%.</li>
<li>Nocera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) shares hit a yearly low of $1.18. The stock was down 5.04% on the session.</li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares moved down 0.53% on Monday to hit a new 52-week low of $0.16, drifting down 0.53%.</li>
<li>OncoSec Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCS#NASDAQ">ONCS</a>) stock dropped to a yearly low on Monday of $2.80. Shares traded down 15.13%.</li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock hit $0.37 on Monday morning, setting a new 52-week low for a change of down 20.68%.</li>
<li>Allied Healthcare Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHPI#NASDAQ">AHPI</a>) stock hit a yearly low of $1.12. The stock was 0.0% (flat) for the day.</li>
<li>Gaucho Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINO#NASDAQ">VINO</a>) shares set a new yearly low of $1.46 this morning. The stock was up 0.11% on the session.</li>
<li>Timber Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TMBR#AMEX">TMBR</a>) shares moved down 4.93% on Monday to hit a new 52-week low of $1.32, drifting down 4.93%.</li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares fell to $0.14 on Monday, setting a new 52-week low with a shift of down 8.94%.</li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) stock achieved a new 52-week low on Monday morning, hitting $0.46 and moving down 7.28%.</li>
<li>Baudax Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BXRX#NASDAQ">BXRX</a>) shares made a new 52-week low of $0.12 on Monday. The stock was down 8.18% for the day.</li>
</ul>
Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. <a href="https://pro.benzinga.com/?afmc=2a&amp;utm_source=benzinga.com&amp;utm_medium=web&amp;utm_campaign=premium_products">Click here to learn more</a>.

Options

ADCT

AEHL

AEVA

AHPI

ARBK

ASTC

ATIP

BRMK

BXRX

CHNR

CYXT

DGLY

EFTR

EKSO

FFWM

GRND

GSUN

IRNT

JZXN

KRON

LCID

LNSR

LODE

LUMN

LVLU

MPAA

NCRA

NDRA

NXTC

ONCS

PRDS

PRSO

RNAZ

SCLX

SDGR

SLDP

SNDA

SNMP

SOFI

SYBX

TMBR

TRKA

TTCF

USDP

VCSA

VINO

VXRT

Stocks That Hit 52-Week Lows On Monday

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

Press Releases

XBiotech Pauses Rheumatology program

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

Legal

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

Comments

XBiotech

Notizie

Ultime notizie per XBiotech (NASDAQ:XBIT) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO